- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06118983
Melhorando as transições e os resultados para pacientes com insuficiência cardíaca em cuidados de saúde domiciliares (I-TRANSFER-HF): um ensaio de implementação de eficácia híbrida tipo 1
This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments.
The study is interested in two questions:
- Is I-TRANSFER-HF better than usual care at preventing heart failure patients from returning to the hospital within 30 days?
- Are there parts of I-TRANSFER-HF that are easy or hard to implement in the real world?
The researchers will answer these questions by testing the intervention among pairs of hospitals and home health agencies across the country. During the study, the hospital-agency pairs will be asked to implement I-TRANSFER-HF. The researchers will then compare the results from before and after I-TRANSFER-HF was adopted. They will also interview people from these hospitals and agencies to see how I-TRANSFER-HF is being implemented under real-world conditions.
Visão geral do estudo
Descrição detalhada
The investigators' will test two hypotheses:
Hypothesis 1 (H1): Compared to usual care, adults with heart failure who receive the I-TRANSFER-HF intervention will have fewer 30-day readmissions, ED visits, and greater days at home. The four hospital-agency pairs will all begin the study with a baseline period of no intervention and then randomly selected to start the intervention phase at different points in time. Medicare claims data from each hospital-agency pair will be used to determine outcomes, and these data will be supplemented with national claims data for external controls not in the study to test the effectiveness of the I-TRANSFER-HF intervention.
Hypothesis 2 (H2): Compared to usual care, heart failure patients who receive I-TRANSFER-HF will have a higher proportion of timely first week HHC nursing visits (within 2 days of hospital discharge, plus 2 more) and outpatient visits (within 7-days of discharge). Given the rise of telemedicine, the study will test the association between the type of outpatient visit (in-person vs. virtual), its timing, and its association with outcomes. H2 requires conducting qualitative interviews with key stakeholders across the 4 hospital-agency pairs to identify barriers and facilitators that influence I-TRANSFER-HF's implementation. The study will assess the intervention's acceptability, feasibility, fidelity, and adaptation with interviews and Medicare claims data using a multi-methods approach and guided by the updated Consolidated Framework for Implementation Research (CFIR 2.0).
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Madeline R Sterling, MD, MPH, MS
- Número de telefone: 6469625029
- E-mail: mrs9012@med.cornell.edu
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Recrutamento
- Weill Cornell Medicine
-
Contato:
- Madeline R Sterling, MD, MPH, MS
- Número de telefone: 646-962-5029
- E-mail: mrs9012@med.cornell.edu
-
Investigador principal:
- Madeline R Sterling, MD, MPH, MS
-
New York, New York, Estados Unidos, 10017
- Recrutamento
- VNS Health Partners in Care
-
Contato:
- Kathy Bowles, PhD, RN,FAAN
- E-mail: bowles@nursing.upenn.edu
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Aim 1, Inclusion Criteria:
- Adults hospitalized for HF who transition from participating hospitals to their partner HHC agency during the study period.
Aim 1, Exclusion Criteria:
- Patients hospitalized for HF and discharged: home without HHC, or to an inpatient rehabilitation facility, skilled nursing facility, or hospice; patients with end stage renal disease on dialysis and those with left ventricular devices.
Aim 2, Inclusion Criteria:
- Healthcare professional involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
Aim 2, Exclusion Criteria:
- Healthcare professional not involved in the transition of heart failure patients from the acute care setting (hospital) to HHC (home health care) agencies, and the implementation of the I-TRANSFER-HF at one of the four participating hospital-HHC dyads.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: I-TRANSFER-HF
This is a 1-year long intervention period when I-TRANSFER-HF is in operation. |
I-TRANSFER-HF is comprised of early and intensive HHC nurse visits and an outpatient visit within 7 days of discharge. Using a Hybrid Type 1, stepped wedge randomized trial design, we will test the effectiveness and implementation of I-TRANSFER-HF in partnership with 4 geographically diverse dyads of hospitals and HHC agencies ("hospital-HHC agency" dyads) across the US. |
|
Sem intervenção: Standard of Care (usual care)
This is a baseline period of usual care (UC) with no intervention. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All-cause 30-day hospital readmission
Prazo: 30 days following post-Index HF Hospitalization
|
All-cause 30-day hospital readmission among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims |
30 days following post-Index HF Hospitalization
|
|
Number of Eligible patients
Prazo: 12 months
|
Number of heart failure patients eligible to receive I-TRANSFER-HF as assessed by Medicare claims data |
12 months
|
|
Number of Eligible Patients Who Received Protocol Components
Prazo: 12 months
|
Number of heart failure patients who received both components of I-TRANSFER-HF (front-loaded home health nurse visits and early outpatient medical follow-up), one, or none as assessed by Medicare claims data |
12 months
|
|
Modality of outpatient follow-up
Prazo: 12 months
|
The modality of outpatient follow-up received (in-person vs. virtual visit) as assessed by Medicare claims data |
12 months
|
|
Timeliness of Post-Hospital Discharge Home Health Nursing Evaluation
Prazo: 12 months
|
The timeliness of first-week nursing visits within 2 days of hospital discharge as assessed by Medicare claims data |
12 months
|
|
Timeliness of Post-Hospital Outpatient Follow-Up
Prazo: 12 months
|
The timeliness of outpatient visits within 7 days of hospital discharge as assessed by Medicare claims data |
12 months
|
|
Feasibility of implementing I-TRANSFER-HF (Qualitative Interviews)
Prazo: 30 days after intervention (year of intervention)
|
Feasibility will be assessed through qualitative interviews with site stakeholders |
30 days after intervention (year of intervention)
|
|
Feasibility of implementing I-TRANSFER-HF (Surveys)
Prazo: 30 days after intervention (year of intervention)
|
Feasibility will be measured through the completion of the validated, 4-item, Feasibility of Intervention Measure (FIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived feasibility of the intervention. |
30 days after intervention (year of intervention)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
All-cause 30-day ED visits
Prazo: 30 days following post-Index heart failure Hospitalization.
|
All-cause 30-day emergency department visits among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims data |
30 days following post-Index heart failure Hospitalization.
|
|
Days at home among adults hospitalized for heart failure who receive home health care after discharge and receive the I-TRANSFER-HF protocol compared to usual care, as assessed by Medicare claims
Prazo: During a 12-month period (year of intervention)
|
Days at home will be calculated as 365 days minus the number of inpatient days in an acute care facility, an inpatient rehabilitation facility, a skilled nursing facility, or an inpatient hospice unit. |
During a 12-month period (year of intervention)
|
|
Acceptability of I-TRANSFER-HF - Qualitative Interviews
Prazo: 30 days after intervention (year of intervention)
|
Acceptability will be assessed through qualitative interviews. |
30 days after intervention (year of intervention)
|
|
Acceptability of Intervention Measure for the I-TRANSFER-HF Study - Survey
Prazo: 30 days after intervention (year of intervention)
|
Acceptability will be assessed through the 4-item, validated, Acceptability of Intervention Measure (AIM). Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). The score is calculated as the mean. The scale for this measure ranges from 4-20 with higher scores indicating greater perceived acceptability of the intervention. |
30 days after intervention (year of intervention)
|
|
Fidelity of I-TRANSFER-HF (Participant-Completed)
Prazo: 30 days after intervention (year of intervention)
|
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using participant-completed fidelity checklists. These checklists will be developed during the implementation process. |
30 days after intervention (year of intervention)
|
|
Fidelity of I-TRANSFER-HF (Observational Ratings)
Prazo: 30 days after intervention (year of intervention)
|
Fidelity will be assessed by extent to which I-TRANSFER-HF is implemented by the study site teams. Fidelity will be measured using observational fidelity ratings conducted by site champions. These checklists will be developed during the implementation process. |
30 days after intervention (year of intervention)
|
|
Adaptation of I-TRANSFER-HF
Prazo: 30 days after intervention (year of intervention)
|
Adaptation will be assessed with qualitative interviews to document how the intervention was modified and refined during the study period. |
30 days after intervention (year of intervention)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Madeline R Sterling, MD, MPH, MS, Weill Medical College of Cornell University
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 23-06026204
- R01HL169312 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .